nodes	percent_of_prediction	percent_of_DWPC	metapath
Afatinib—ABCG2—Rosuvastatin—atherosclerosis	0.137	0.235	CbGbCtD
Afatinib—ABCG2—Ezetimibe—atherosclerosis	0.137	0.235	CbGbCtD
Afatinib—ABCG2—Pravastatin—atherosclerosis	0.124	0.213	CbGbCtD
Afatinib—ABCB1—Ezetimibe—atherosclerosis	0.0493	0.0846	CbGbCtD
Afatinib—ABCB1—Simvastatin—atherosclerosis	0.0458	0.0787	CbGbCtD
Afatinib—ABCB1—Pravastatin—atherosclerosis	0.0448	0.077	CbGbCtD
Afatinib—ABCB1—Lovastatin—atherosclerosis	0.0448	0.077	CbGbCtD
Afatinib—Interstitial lung disease—Ezetimibe—atherosclerosis	0.0034	0.0263	CcSEcCtD
Afatinib—Interstitial lung disease—Simvastatin—atherosclerosis	0.00324	0.0251	CcSEcCtD
Afatinib—Interstitial lung disease—Pravastatin—atherosclerosis	0.00293	0.0227	CcSEcCtD
Afatinib—ERBB2—connective tissue—atherosclerosis	0.0028	0.0735	CbGeAlD
Afatinib—ERBB4—cardiovascular system—atherosclerosis	0.00244	0.0639	CbGeAlD
Afatinib—ERBB2—cardiovascular system—atherosclerosis	0.00244	0.0639	CbGeAlD
Afatinib—PHKG2—adipose tissue—atherosclerosis	0.00239	0.0627	CbGeAlD
Afatinib—DYRK1A—cardiovascular system—atherosclerosis	0.00234	0.0616	CbGeAlD
Afatinib—Vandetanib—VEGFA—atherosclerosis	0.0023	0.656	CrCbGaD
Afatinib—ERBB2—adipose tissue—atherosclerosis	0.00215	0.0564	CbGeAlD
Afatinib—ERBB4—adipose tissue—atherosclerosis	0.00215	0.0564	CbGeAlD
Afatinib—DYRK1A—adipose tissue—atherosclerosis	0.00207	0.0543	CbGeAlD
Afatinib—EGFR—adipose tissue—atherosclerosis	0.00182	0.0478	CbGeAlD
Afatinib—PHKG2—liver—atherosclerosis	0.00168	0.044	CbGeAlD
Afatinib—IRAK1—adipose tissue—atherosclerosis	0.00161	0.0422	CbGeAlD
Afatinib—Urinary tract infection—Rosuvastatin—atherosclerosis	0.00157	0.0122	CcSEcCtD
Afatinib—Aspartate aminotransferase increased—Ezetimibe—atherosclerosis	0.00157	0.0122	CcSEcCtD
Afatinib—LCK—adipose tissue—atherosclerosis	0.00157	0.0411	CbGeAlD
Afatinib—Nasopharyngitis—Ezetimibe—atherosclerosis	0.00156	0.0121	CcSEcCtD
Afatinib—Alanine aminotransferase increased—Ezetimibe—atherosclerosis	0.00154	0.0119	CcSEcCtD
Afatinib—Hepatobiliary disease—Rosuvastatin—atherosclerosis	0.00153	0.0119	CcSEcCtD
Afatinib—ERBB2—liver—atherosclerosis	0.00151	0.0395	CbGeAlD
Afatinib—DYRK1A—liver—atherosclerosis	0.00145	0.0381	CbGeAlD
Afatinib—Upper respiratory tract infection—Ezetimibe—atherosclerosis	0.0014	0.0109	CcSEcCtD
Afatinib—Dry skin—Niacin—atherosclerosis	0.0014	0.0109	CcSEcCtD
Afatinib—Dry skin—Pravastatin—atherosclerosis	0.00138	0.0107	CcSEcCtD
Afatinib—Nasopharyngitis—Pravastatin—atherosclerosis	0.00135	0.0104	CcSEcCtD
Afatinib—Infestation—Ezetimibe—atherosclerosis	0.00134	0.0104	CcSEcCtD
Afatinib—Infestation NOS—Ezetimibe—atherosclerosis	0.00134	0.0104	CcSEcCtD
Afatinib—Upper respiratory tract infection—Simvastatin—atherosclerosis	0.00134	0.0104	CcSEcCtD
Afatinib—Urinary tract infection—Lovastatin—atherosclerosis	0.00133	0.0103	CcSEcCtD
Afatinib—Alanine aminotransferase increased—Pravastatin—atherosclerosis	0.00133	0.0103	CcSEcCtD
Afatinib—EGFR—liver—atherosclerosis	0.00128	0.0335	CbGeAlD
Afatinib—Mental disorder—Rosuvastatin—atherosclerosis	0.00127	0.00986	CcSEcCtD
Afatinib—Hepatobiliary disease—Ezetimibe—atherosclerosis	0.00127	0.00986	CcSEcCtD
Afatinib—Upper respiratory tract infection—Pravastatin—atherosclerosis	0.00121	0.00937	CcSEcCtD
Afatinib—Connective tissue disorder—Ezetimibe—atherosclerosis	0.00119	0.0092	CcSEcCtD
Afatinib—Weight decreased—Pravastatin—atherosclerosis	0.00118	0.00912	CcSEcCtD
Afatinib—ABL1—connective tissue—atherosclerosis	0.00117	0.0308	CbGeAlD
Afatinib—Stomatitis—Niacin—atherosclerosis	0.00115	0.0089	CcSEcCtD
Afatinib—IRAK1—liver—atherosclerosis	0.00113	0.0296	CbGeAlD
Afatinib—Urinary tract infection—Pravastatin—atherosclerosis	0.00113	0.00874	CcSEcCtD
Afatinib—Cough—Rosuvastatin—atherosclerosis	0.0011	0.00855	CcSEcCtD
Afatinib—LCK—liver—atherosclerosis	0.0011	0.0288	CbGeAlD
Afatinib—Mediastinal disorder—Ezetimibe—atherosclerosis	0.00109	0.00843	CcSEcCtD
Afatinib—Alopecia—Lovastatin—atherosclerosis	0.00109	0.00843	CcSEcCtD
Afatinib—Alopecia—Ezetimibe—atherosclerosis	0.00107	0.00827	CcSEcCtD
Afatinib—Mental disorder—Ezetimibe—atherosclerosis	0.00106	0.0082	CcSEcCtD
Afatinib—Malnutrition—Ezetimibe—atherosclerosis	0.00105	0.00815	CcSEcCtD
Afatinib—Dysgeusia—Lovastatin—atherosclerosis	0.00105	0.00813	CcSEcCtD
Afatinib—Back pain—Lovastatin—atherosclerosis	0.00104	0.00803	CcSEcCtD
Afatinib—Muscle spasms—Lovastatin—atherosclerosis	0.00103	0.00799	CcSEcCtD
Afatinib—Infection—Rosuvastatin—atherosclerosis	0.00102	0.00795	CcSEcCtD
Afatinib—ABL1—cardiovascular system—atherosclerosis	0.00102	0.0268	CbGeAlD
Afatinib—Alopecia—Simvastatin—atherosclerosis	0.00102	0.00789	CcSEcCtD
Afatinib—Back pain—Ezetimibe—atherosclerosis	0.00102	0.00788	CcSEcCtD
Afatinib—Nervous system disorder—Rosuvastatin—atherosclerosis	0.00101	0.00784	CcSEcCtD
Afatinib—Muscle spasms—Ezetimibe—atherosclerosis	0.00101	0.00783	CcSEcCtD
Afatinib—Mental disorder—Simvastatin—atherosclerosis	0.00101	0.00782	CcSEcCtD
Afatinib—Eye disorder—Niacin—atherosclerosis	0.000988	0.00766	CcSEcCtD
Afatinib—Dysgeusia—Simvastatin—atherosclerosis	0.000981	0.00761	CcSEcCtD
Afatinib—Muscle spasms—Simvastatin—atherosclerosis	0.000963	0.00747	CcSEcCtD
Afatinib—Alopecia—Niacin—atherosclerosis	0.000934	0.00724	CcSEcCtD
Afatinib—Insomnia—Rosuvastatin—atherosclerosis	0.000933	0.00724	CcSEcCtD
Afatinib—Malnutrition—Niacin—atherosclerosis	0.00092	0.00713	CcSEcCtD
Afatinib—Alopecia—Pravastatin—atherosclerosis	0.00092	0.00713	CcSEcCtD
Afatinib—Cough—Ezetimibe—atherosclerosis	0.000917	0.00711	CcSEcCtD
Afatinib—Dyspepsia—Rosuvastatin—atherosclerosis	0.000908	0.00704	CcSEcCtD
Afatinib—ABL1—adipose tissue—atherosclerosis	0.0009	0.0236	CbGeAlD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	0.000888	0.00689	CcSEcCtD
Afatinib—Dysgeusia—Pravastatin—atherosclerosis	0.000887	0.00688	CcSEcCtD
Afatinib—Muscle spasms—Niacin—atherosclerosis	0.000885	0.00686	CcSEcCtD
Afatinib—Constipation—Rosuvastatin—atherosclerosis	0.000882	0.00684	CcSEcCtD
Afatinib—Muscle spasms—Pravastatin—atherosclerosis	0.000871	0.00675	CcSEcCtD
Afatinib—Infection—Lovastatin—atherosclerosis	0.000869	0.00674	CcSEcCtD
Afatinib—Infection—Ezetimibe—atherosclerosis	0.000852	0.00661	CcSEcCtD
Afatinib—Nervous system disorder—Ezetimibe—atherosclerosis	0.000841	0.00652	CcSEcCtD
Afatinib—Skin disorder—Ezetimibe—atherosclerosis	0.000833	0.00646	CcSEcCtD
Afatinib—Infection—Simvastatin—atherosclerosis	0.000812	0.0063	CcSEcCtD
Afatinib—Cough—Niacin—atherosclerosis	0.000803	0.00623	CcSEcCtD
Afatinib—Insomnia—Lovastatin—atherosclerosis	0.000791	0.00613	CcSEcCtD
Afatinib—Cough—Pravastatin—atherosclerosis	0.00079	0.00613	CcSEcCtD
Afatinib—Dyspnoea—Lovastatin—atherosclerosis	0.000779	0.00604	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	0.000778	0.00603	CcSEcCtD
Afatinib—Insomnia—Ezetimibe—atherosclerosis	0.000776	0.00601	CcSEcCtD
Afatinib—Dyspepsia—Lovastatin—atherosclerosis	0.00077	0.00597	CcSEcCtD
Afatinib—Dyspnoea—Ezetimibe—atherosclerosis	0.000764	0.00593	CcSEcCtD
Afatinib—Decreased appetite—Lovastatin—atherosclerosis	0.00076	0.00589	CcSEcCtD
Afatinib—Dyspepsia—Ezetimibe—atherosclerosis	0.000755	0.00585	CcSEcCtD
Afatinib—Fatigue—Lovastatin—atherosclerosis	0.000754	0.00584	CcSEcCtD
Afatinib—Constipation—Lovastatin—atherosclerosis	0.000748	0.0058	CcSEcCtD
Afatinib—Decreased appetite—Ezetimibe—atherosclerosis	0.000745	0.00578	CcSEcCtD
Afatinib—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.00074	0.00574	CcSEcCtD
Afatinib—Asthenia—Rosuvastatin—atherosclerosis	0.00074	0.00574	CcSEcCtD
Afatinib—Insomnia—Simvastatin—atherosclerosis	0.00074	0.00574	CcSEcCtD
Afatinib—Fatigue—Ezetimibe—atherosclerosis	0.000739	0.00573	CcSEcCtD
Afatinib—Infection—Pravastatin—atherosclerosis	0.000734	0.0057	CcSEcCtD
Afatinib—Constipation—Ezetimibe—atherosclerosis	0.000733	0.00569	CcSEcCtD
Afatinib—Pruritus—Rosuvastatin—atherosclerosis	0.00073	0.00566	CcSEcCtD
Afatinib—Skin disorder—Niacin—atherosclerosis	0.000729	0.00566	CcSEcCtD
Afatinib—Dyspnoea—Simvastatin—atherosclerosis	0.000729	0.00565	CcSEcCtD
Afatinib—Dyspepsia—Simvastatin—atherosclerosis	0.00072	0.00558	CcSEcCtD
Afatinib—ABCB1—blood vessel—atherosclerosis	0.000711	0.0187	CbGeAlD
Afatinib—Decreased appetite—Simvastatin—atherosclerosis	0.000711	0.00551	CcSEcCtD
Afatinib—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.000706	0.00547	CcSEcCtD
Afatinib—Diarrhoea—Rosuvastatin—atherosclerosis	0.000706	0.00547	CcSEcCtD
Afatinib—Fatigue—Simvastatin—atherosclerosis	0.000705	0.00547	CcSEcCtD
Afatinib—Constipation—Simvastatin—atherosclerosis	0.000699	0.00542	CcSEcCtD
Afatinib—Body temperature increased—Lovastatin—atherosclerosis	0.000691	0.00536	CcSEcCtD
Afatinib—Dizziness—Rosuvastatin—atherosclerosis	0.000682	0.00529	CcSEcCtD
Afatinib—Insomnia—Niacin—atherosclerosis	0.000679	0.00527	CcSEcCtD
Afatinib—Body temperature increased—Ezetimibe—atherosclerosis	0.000678	0.00526	CcSEcCtD
Afatinib—Dyspnoea—Niacin—atherosclerosis	0.000669	0.00519	CcSEcCtD
Afatinib—Insomnia—Pravastatin—atherosclerosis	0.000669	0.00519	CcSEcCtD
Afatinib—Dyspepsia—Niacin—atherosclerosis	0.000661	0.00513	CcSEcCtD
Afatinib—Dyspnoea—Pravastatin—atherosclerosis	0.000659	0.00511	CcSEcCtD
Afatinib—Decreased appetite—Niacin—atherosclerosis	0.000653	0.00506	CcSEcCtD
Afatinib—Dyspepsia—Pravastatin—atherosclerosis	0.000651	0.00505	CcSEcCtD
Afatinib—Rash—Rosuvastatin—atherosclerosis	0.00065	0.00504	CcSEcCtD
Afatinib—Dermatitis—Rosuvastatin—atherosclerosis	0.00065	0.00504	CcSEcCtD
Afatinib—Gastrointestinal disorder—Niacin—atherosclerosis	0.000648	0.00503	CcSEcCtD
Afatinib—Body temperature increased—Simvastatin—atherosclerosis	0.000646	0.00501	CcSEcCtD
Afatinib—Headache—Rosuvastatin—atherosclerosis	0.000646	0.00501	CcSEcCtD
Afatinib—Decreased appetite—Pravastatin—atherosclerosis	0.000643	0.00498	CcSEcCtD
Afatinib—Fatigue—Pravastatin—atherosclerosis	0.000637	0.00494	CcSEcCtD
Afatinib—Constipation—Pravastatin—atherosclerosis	0.000632	0.0049	CcSEcCtD
Afatinib—ABL1—liver—atherosclerosis	0.000631	0.0166	CbGeAlD
Afatinib—Asthenia—Lovastatin—atherosclerosis	0.000627	0.00486	CcSEcCtD
Afatinib—Vandetanib—ALB—atherosclerosis	0.000619	0.176	CrCbGaD
Afatinib—Pruritus—Lovastatin—atherosclerosis	0.000619	0.0048	CcSEcCtD
Afatinib—Asthenia—Ezetimibe—atherosclerosis	0.000615	0.00477	CcSEcCtD
Afatinib—Nausea—Rosuvastatin—atherosclerosis	0.000613	0.00475	CcSEcCtD
Afatinib—Pruritus—Ezetimibe—atherosclerosis	0.000607	0.0047	CcSEcCtD
Afatinib—Diarrhoea—Lovastatin—atherosclerosis	0.000598	0.00464	CcSEcCtD
Afatinib—Body temperature increased—Niacin—atherosclerosis	0.000594	0.0046	CcSEcCtD
Afatinib—Gefitinib—ALB—atherosclerosis	0.000588	0.168	CrCbGaD
Afatinib—Asthenia—Simvastatin—atherosclerosis	0.000587	0.00455	CcSEcCtD
Afatinib—Diarrhoea—Ezetimibe—atherosclerosis	0.000587	0.00455	CcSEcCtD
Afatinib—Body temperature increased—Pravastatin—atherosclerosis	0.000584	0.00453	CcSEcCtD
Afatinib—Pruritus—Simvastatin—atherosclerosis	0.000579	0.00449	CcSEcCtD
Afatinib—Dizziness—Lovastatin—atherosclerosis	0.000578	0.00448	CcSEcCtD
Afatinib—ABCG2—adipose tissue—atherosclerosis	0.000568	0.0149	CbGeAlD
Afatinib—Dizziness—Ezetimibe—atherosclerosis	0.000567	0.0044	CcSEcCtD
Afatinib—Diarrhoea—Simvastatin—atherosclerosis	0.000559	0.00434	CcSEcCtD
Afatinib—Vomiting—Lovastatin—atherosclerosis	0.000556	0.00431	CcSEcCtD
Afatinib—Rash—Lovastatin—atherosclerosis	0.000551	0.00427	CcSEcCtD
Afatinib—Dermatitis—Lovastatin—atherosclerosis	0.000551	0.00427	CcSEcCtD
Afatinib—Headache—Lovastatin—atherosclerosis	0.000548	0.00425	CcSEcCtD
Afatinib—Vomiting—Ezetimibe—atherosclerosis	0.000545	0.00423	CcSEcCtD
Afatinib—Dizziness—Simvastatin—atherosclerosis	0.000541	0.00419	CcSEcCtD
Afatinib—Rash—Ezetimibe—atherosclerosis	0.000541	0.00419	CcSEcCtD
Afatinib—Dermatitis—Ezetimibe—atherosclerosis	0.00054	0.00419	CcSEcCtD
Afatinib—Asthenia—Niacin—atherosclerosis	0.000539	0.00418	CcSEcCtD
Afatinib—Headache—Ezetimibe—atherosclerosis	0.000537	0.00417	CcSEcCtD
Afatinib—Pruritus—Niacin—atherosclerosis	0.000531	0.00412	CcSEcCtD
Afatinib—Asthenia—Pravastatin—atherosclerosis	0.00053	0.00411	CcSEcCtD
Afatinib—Pruritus—Pravastatin—atherosclerosis	0.000523	0.00406	CcSEcCtD
Afatinib—Vomiting—Simvastatin—atherosclerosis	0.00052	0.00403	CcSEcCtD
Afatinib—Nausea—Lovastatin—atherosclerosis	0.000519	0.00403	CcSEcCtD
Afatinib—Rash—Simvastatin—atherosclerosis	0.000516	0.004	CcSEcCtD
Afatinib—Dermatitis—Simvastatin—atherosclerosis	0.000515	0.00399	CcSEcCtD
Afatinib—Diarrhoea—Niacin—atherosclerosis	0.000514	0.00398	CcSEcCtD
Afatinib—Headache—Simvastatin—atherosclerosis	0.000512	0.00397	CcSEcCtD
Afatinib—Nausea—Ezetimibe—atherosclerosis	0.000509	0.00395	CcSEcCtD
Afatinib—Diarrhoea—Pravastatin—atherosclerosis	0.000506	0.00392	CcSEcCtD
Afatinib—Dizziness—Niacin—atherosclerosis	0.000497	0.00385	CcSEcCtD
Afatinib—Dizziness—Pravastatin—atherosclerosis	0.000489	0.00379	CcSEcCtD
Afatinib—Nausea—Simvastatin—atherosclerosis	0.000486	0.00377	CcSEcCtD
Afatinib—Vomiting—Niacin—atherosclerosis	0.000477	0.0037	CcSEcCtD
Afatinib—Rash—Niacin—atherosclerosis	0.000473	0.00367	CcSEcCtD
Afatinib—Dermatitis—Niacin—atherosclerosis	0.000473	0.00367	CcSEcCtD
Afatinib—Headache—Niacin—atherosclerosis	0.00047	0.00365	CcSEcCtD
Afatinib—Vomiting—Pravastatin—atherosclerosis	0.00047	0.00365	CcSEcCtD
Afatinib—Rash—Pravastatin—atherosclerosis	0.000466	0.00361	CcSEcCtD
Afatinib—Dermatitis—Pravastatin—atherosclerosis	0.000466	0.00361	CcSEcCtD
Afatinib—Headache—Pravastatin—atherosclerosis	0.000463	0.00359	CcSEcCtD
Afatinib—Nausea—Niacin—atherosclerosis	0.000446	0.00346	CcSEcCtD
Afatinib—Nausea—Pravastatin—atherosclerosis	0.000439	0.00341	CcSEcCtD
Afatinib—ABCG2—liver—atherosclerosis	0.000398	0.0104	CbGeAlD
Afatinib—ABCB1—cardiovascular system—atherosclerosis	0.000317	0.00833	CbGeAlD
Afatinib—ABCB1—adipose tissue—atherosclerosis	0.00028	0.00735	CbGeAlD
Afatinib—ABCB1—liver—atherosclerosis	0.000196	0.00515	CbGeAlD
Afatinib—IRAK1—Signaling Pathways—ESR1—atherosclerosis	1.56e-05	6.32e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—APOA5—atherosclerosis	1.56e-05	6.31e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—CCL2—atherosclerosis	1.56e-05	6.3e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—CAV1—atherosclerosis	1.55e-05	6.27e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PLG—atherosclerosis	1.55e-05	6.26e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—APOA1—atherosclerosis	1.55e-05	6.25e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—F2—atherosclerosis	1.55e-05	6.25e-05	CbGpPWpGaD
Afatinib—LCK—Hemostasis—TGFB1—atherosclerosis	1.54e-05	6.24e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—KNG1—atherosclerosis	1.54e-05	6.23e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—ICAM1—atherosclerosis	1.53e-05	6.2e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—AGTR1—atherosclerosis	1.53e-05	6.19e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—APOB—atherosclerosis	1.53e-05	6.18e-05	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—TNF—atherosclerosis	1.52e-05	6.16e-05	CbGpPWpGaD
Afatinib—LCK—Disease—APOE—atherosclerosis	1.51e-05	6.1e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—NFKB1—atherosclerosis	1.51e-05	6.09e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—CXCL8—atherosclerosis	1.51e-05	6.09e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PLA2G1B—atherosclerosis	1.5e-05	6.07e-05	CbGpPWpGaD
Afatinib—IRAK1—Innate Immune System—AKT1—atherosclerosis	1.5e-05	6.06e-05	CbGpPWpGaD
Afatinib—LCK—Disease—CAV1—atherosclerosis	1.49e-05	6.04e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PLG—atherosclerosis	1.49e-05	6.03e-05	CbGpPWpGaD
Afatinib—LCK—Disease—APOA1—atherosclerosis	1.49e-05	6.03e-05	CbGpPWpGaD
Afatinib—ABCB1—Transmembrane transport of small molecules—PPARA—atherosclerosis	1.49e-05	6.02e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—GSTM1—atherosclerosis	1.49e-05	6.01e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—MAPK3—atherosclerosis	1.49e-05	6.01e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—CXCL8—atherosclerosis	1.48e-05	6e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—MAPK8—atherosclerosis	1.48e-05	5.99e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—PIK3CG—atherosclerosis	1.48e-05	5.98e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—SOCS3—atherosclerosis	1.47e-05	5.93e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—LPL—atherosclerosis	1.46e-05	5.9e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—NOS2—atherosclerosis	1.46e-05	5.89e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—ALOX5—atherosclerosis	1.45e-05	5.86e-05	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—IL6—atherosclerosis	1.44e-05	5.82e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—MAPK3—atherosclerosis	1.43e-05	5.79e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—GPX1—atherosclerosis	1.42e-05	5.76e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—IFNG—atherosclerosis	1.42e-05	5.73e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MMP3—atherosclerosis	1.42e-05	5.73e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—SOCS3—atherosclerosis	1.41e-05	5.71e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—IGF2—atherosclerosis	1.41e-05	5.7e-05	CbGpPWpGaD
Afatinib—LCK—Disease—NOS2—atherosclerosis	1.41e-05	5.68e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—INS—atherosclerosis	1.4e-05	5.66e-05	CbGpPWpGaD
Afatinib—ABCB1—Transmembrane transport of small molecules—APOA1—atherosclerosis	1.4e-05	5.64e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—CD36—atherosclerosis	1.39e-05	5.61e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CCL2—atherosclerosis	1.38e-05	5.57e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—APOB—atherosclerosis	1.37e-05	5.53e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MMP3—atherosclerosis	1.36e-05	5.52e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—MMP9—atherosclerosis	1.36e-05	5.51e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—IGF2—atherosclerosis	1.36e-05	5.49e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—STAT3—atherosclerosis	1.35e-05	5.48e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—IGF1—atherosclerosis	1.35e-05	5.47e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—NFKB1—atherosclerosis	1.35e-05	5.45e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—EDN1—atherosclerosis	1.35e-05	5.45e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—MMP9—atherosclerosis	1.34e-05	5.42e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CCL5—atherosclerosis	1.34e-05	5.4e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—INS—atherosclerosis	1.34e-05	5.4e-05	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—AKT1—atherosclerosis	1.33e-05	5.37e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—NFKB1—atherosclerosis	1.33e-05	5.37e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—MAPK8—atherosclerosis	1.32e-05	5.36e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—APOB—atherosclerosis	1.32e-05	5.33e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—MTHFR—atherosclerosis	1.31e-05	5.31e-05	CbGpPWpGaD
Afatinib—ERBB2—Immune System—IL6—atherosclerosis	1.31e-05	5.29e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—LPL—atherosclerosis	1.31e-05	5.28e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—MAPK8—atherosclerosis	1.31e-05	5.28e-05	CbGpPWpGaD
Afatinib—ABL1—Hemostasis—AKT1—atherosclerosis	1.3e-05	5.27e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—NAMPT—atherosclerosis	1.3e-05	5.26e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—EDN1—atherosclerosis	1.3e-05	5.25e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—MAPK3—atherosclerosis	1.29e-05	5.23e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—LIPC—atherosclerosis	1.29e-05	5.23e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PPARA—atherosclerosis	1.29e-05	5.21e-05	CbGpPWpGaD
Afatinib—ERBB4—Immune System—IL6—atherosclerosis	1.29e-05	5.21e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CCL5—atherosclerosis	1.29e-05	5.21e-05	CbGpPWpGaD
Afatinib—LCK—Disease—INS—atherosclerosis	1.29e-05	5.21e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—SERPINE1—atherosclerosis	1.29e-05	5.2e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—APOC3—atherosclerosis	1.28e-05	5.2e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—LDLR—atherosclerosis	1.28e-05	5.16e-05	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—IL6—atherosclerosis	1.27e-05	5.14e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PRKCG—atherosclerosis	1.27e-05	5.14e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—IL1B—atherosclerosis	1.26e-05	5.11e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—LPL—atherosclerosis	1.26e-05	5.09e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—AGT—atherosclerosis	1.25e-05	5.05e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CETP—atherosclerosis	1.25e-05	5.04e-05	CbGpPWpGaD
Afatinib—BLK—Immune System—IL6—atherosclerosis	1.24e-05	5.01e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—SPP1—atherosclerosis	1.24e-05	5.01e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—CXCL8—atherosclerosis	1.23e-05	4.98e-05	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—IL6—atherosclerosis	1.23e-05	4.97e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—SERPINE1—atherosclerosis	1.23e-05	4.96e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—NOS3—atherosclerosis	1.23e-05	4.96e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PRKCG—atherosclerosis	1.22e-05	4.95e-05	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—atherosclerosis	1.22e-05	4.95e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—APOE—atherosclerosis	1.22e-05	4.95e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—VEGFA—atherosclerosis	1.22e-05	4.95e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—CAV1—atherosclerosis	1.21e-05	4.9e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—STAT3—atherosclerosis	1.21e-05	4.9e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—IFNG—atherosclerosis	1.21e-05	4.9e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—APOA1—atherosclerosis	1.21e-05	4.89e-05	CbGpPWpGaD
Afatinib—ERBB2—Disease—IL6—atherosclerosis	1.21e-05	4.88e-05	CbGpPWpGaD
Afatinib—ERBB2—Immune System—AKT1—atherosclerosis	1.21e-05	4.88e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—VEGFA—atherosclerosis	1.2e-05	4.87e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—SCARB1—atherosclerosis	1.19e-05	4.83e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—STAT3—atherosclerosis	1.19e-05	4.82e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—SPP1—atherosclerosis	1.19e-05	4.82e-05	CbGpPWpGaD
Afatinib—ERBB4—Disease—IL6—atherosclerosis	1.19e-05	4.81e-05	CbGpPWpGaD
Afatinib—ERBB4—Immune System—AKT1—atherosclerosis	1.19e-05	4.81e-05	CbGpPWpGaD
Afatinib—LCK—Disease—SERPINE1—atherosclerosis	1.18e-05	4.78e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—NFKB1—atherosclerosis	1.18e-05	4.77e-05	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—AKT1—atherosclerosis	1.17e-05	4.74e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—NOS3—atherosclerosis	1.17e-05	4.74e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—IFNG—atherosclerosis	1.17e-05	4.72e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—MAPK8—atherosclerosis	1.16e-05	4.69e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—MAPK3—atherosclerosis	1.16e-05	4.68e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PDGFB—atherosclerosis	1.15e-05	4.63e-05	CbGpPWpGaD
Afatinib—BLK—Immune System—AKT1—atherosclerosis	1.14e-05	4.62e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—MAPK3—atherosclerosis	1.14e-05	4.61e-05	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—AKT1—atherosclerosis	1.13e-05	4.59e-05	CbGpPWpGaD
Afatinib—LCK—Disease—NOS3—atherosclerosis	1.13e-05	4.57e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—HMGCR—atherosclerosis	1.13e-05	4.56e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—TGFB1—atherosclerosis	1.12e-05	4.54e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—AGT—atherosclerosis	1.12e-05	4.52e-05	CbGpPWpGaD
Afatinib—ERBB2—Disease—AKT1—atherosclerosis	1.11e-05	4.51e-05	CbGpPWpGaD
Afatinib—ABCB1—Transmembrane transport of small molecules—ALB—atherosclerosis	1.11e-05	4.47e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—TGFB1—atherosclerosis	1.11e-05	4.47e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PIK3CG—atherosclerosis	1.1e-05	4.46e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PDGFB—atherosclerosis	1.1e-05	4.46e-05	CbGpPWpGaD
Afatinib—ERBB4—Disease—AKT1—atherosclerosis	1.1e-05	4.44e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—LEP—atherosclerosis	1.1e-05	4.43e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—APOE—atherosclerosis	1.1e-05	4.43e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CXCL8—atherosclerosis	1.09e-05	4.4e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—IL6—atherosclerosis	1.09e-05	4.39e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CAV1—atherosclerosis	1.09e-05	4.39e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—APOA1—atherosclerosis	1.08e-05	4.38e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—IL1B—atherosclerosis	1.08e-05	4.37e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—AGT—atherosclerosis	1.08e-05	4.36e-05	CbGpPWpGaD
Afatinib—LCK—Hemostasis—AKT1—atherosclerosis	1.07e-05	4.34e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—PTGS2—atherosclerosis	1.07e-05	4.33e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PPARG—atherosclerosis	1.07e-05	4.31e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—STAT3—atherosclerosis	1.06e-05	4.28e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—APOE—atherosclerosis	1.06e-05	4.27e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—LEP—atherosclerosis	1.06e-05	4.27e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—IL6—atherosclerosis	1.05e-05	4.23e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CAV1—atherosclerosis	1.05e-05	4.23e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—ESR1—atherosclerosis	1.05e-05	4.23e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—INS—atherosclerosis	1.05e-05	4.23e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—APOA1—atherosclerosis	1.04e-05	4.22e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—IL1B—atherosclerosis	1.04e-05	4.21e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—F2—atherosclerosis	1.03e-05	4.18e-05	CbGpPWpGaD
Afatinib—LCK—Disease—PTGS2—atherosclerosis	1.03e-05	4.18e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—MAPK3—atherosclerosis	1.01e-05	4.09e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—ESR1—atherosclerosis	1.01e-05	4.08e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—NFKB1—atherosclerosis	1.01e-05	4.07e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—ABCA1—atherosclerosis	1.01e-05	4.07e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—AKT1—atherosclerosis	1e-05	4.05e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—F2—atherosclerosis	9.96e-06	4.03e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—MAPK8—atherosclerosis	9.91e-06	4.01e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PIK3CG—atherosclerosis	9.89e-06	4e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—MMP9—atherosclerosis	9.85e-06	3.98e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—NFKB1—atherosclerosis	9.74e-06	3.94e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—NFKB1—atherosclerosis	9.71e-06	3.93e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—AKT1—atherosclerosis	9.66e-06	3.9e-05	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—AKT1—atherosclerosis	9.62e-06	3.89e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—ALB—atherosclerosis	9.58e-06	3.87e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—MAPK8—atherosclerosis	9.58e-06	3.87e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—MAPK8—atherosclerosis	9.55e-06	3.86e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PIK3CG—atherosclerosis	9.53e-06	3.85e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—MAPK3—atherosclerosis	9.47e-06	3.83e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—IL6—atherosclerosis	9.46e-06	3.82e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—INS—atherosclerosis	9.36e-06	3.78e-05	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—AKT1—atherosclerosis	9.27e-06	3.75e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CCL2—atherosclerosis	9.21e-06	3.72e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—NOS3—atherosclerosis	9.16e-06	3.71e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—STAT3—atherosclerosis	9.06e-06	3.66e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—IGF1—atherosclerosis	9.05e-06	3.66e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—INS—atherosclerosis	9.02e-06	3.65e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CCL2—atherosclerosis	8.88e-06	3.59e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—VEGFA—atherosclerosis	8.84e-06	3.58e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—STAT3—atherosclerosis	8.76e-06	3.54e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—AKT1—atherosclerosis	8.73e-06	3.53e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—STAT3—atherosclerosis	8.73e-06	3.53e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—IGF1—atherosclerosis	8.73e-06	3.53e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—MAPK3—atherosclerosis	8.65e-06	3.5e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—HMOX1—atherosclerosis	8.63e-06	3.49e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—SERPINE1—atherosclerosis	8.6e-06	3.48e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—IL6—atherosclerosis	8.46e-06	3.42e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PTGS2—atherosclerosis	8.38e-06	3.39e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—MAPK3—atherosclerosis	8.37e-06	3.38e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—STAT3—atherosclerosis	8.36e-06	3.38e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—MAPK3—atherosclerosis	8.34e-06	3.37e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—IL6—atherosclerosis	8.33e-06	3.37e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—SERPINE1—atherosclerosis	8.29e-06	3.35e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—APOB—atherosclerosis	8.26e-06	3.34e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—NOS3—atherosclerosis	8.21e-06	3.32e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—TGFB1—atherosclerosis	8.12e-06	3.28e-05	CbGpPWpGaD
Afatinib—LCK—Disease—STAT3—atherosclerosis	8.06e-06	3.26e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—GSTM1—atherosclerosis	8.04e-06	3.25e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—MAPK3—atherosclerosis	7.99e-06	3.23e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—NOS3—atherosclerosis	7.91e-06	3.2e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—LPL—atherosclerosis	7.89e-06	3.19e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—AKT1—atherosclerosis	7.81e-06	3.16e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—TGFB1—atherosclerosis	7.75e-06	3.13e-05	CbGpPWpGaD
Afatinib—LCK—Disease—MAPK3—atherosclerosis	7.7e-06	3.11e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—GPX1—atherosclerosis	7.7e-06	3.11e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—AKT1—atherosclerosis	7.69e-06	3.11e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CD36—atherosclerosis	7.5e-06	3.03e-05	CbGpPWpGaD
Afatinib—LCK—Disease—TGFB1—atherosclerosis	7.47e-06	3.02e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—IL6—atherosclerosis	7.4e-06	2.99e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CXCL8—atherosclerosis	7.28e-06	2.94e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—MTHFR—atherosclerosis	7.1e-06	2.87e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CXCL8—atherosclerosis	7.02e-06	2.84e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PPARA—atherosclerosis	6.97e-06	2.82e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—IL6—atherosclerosis	6.92e-06	2.8e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—AKT1—atherosclerosis	6.83e-06	2.76e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—AGT—atherosclerosis	6.75e-06	2.73e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—APOE—atherosclerosis	6.61e-06	2.67e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MMP9—atherosclerosis	6.59e-06	2.66e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CAV1—atherosclerosis	6.55e-06	2.65e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—APOA1—atherosclerosis	6.54e-06	2.64e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—NFKB1—atherosclerosis	6.52e-06	2.63e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MAPK8—atherosclerosis	6.4e-06	2.59e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—AKT1—atherosclerosis	6.39e-06	2.58e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MMP9—atherosclerosis	6.35e-06	2.57e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—IL6—atherosclerosis	6.33e-06	2.56e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—NFKB1—atherosclerosis	6.28e-06	2.54e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MAPK8—atherosclerosis	6.17e-06	2.5e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—IL6—atherosclerosis	6.12e-06	2.47e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—IL6—atherosclerosis	6.1e-06	2.46e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PIK3CG—atherosclerosis	5.97e-06	2.41e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—VEGFA—atherosclerosis	5.91e-06	2.39e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—STAT3—atherosclerosis	5.86e-06	2.37e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—IL6—atherosclerosis	5.84e-06	2.36e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—AKT1—atherosclerosis	5.84e-06	2.36e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PPARG—atherosclerosis	5.76e-06	2.33e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—VEGFA—atherosclerosis	5.7e-06	2.3e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—INS—atherosclerosis	5.65e-06	2.28e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—AKT1—atherosclerosis	5.64e-06	2.28e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—STAT3—atherosclerosis	5.64e-06	2.28e-05	CbGpPWpGaD
Afatinib—LCK—Disease—IL6—atherosclerosis	5.63e-06	2.28e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—AKT1—atherosclerosis	5.62e-06	2.27e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MAPK3—atherosclerosis	5.59e-06	2.26e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—TGFB1—atherosclerosis	5.43e-06	2.19e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MAPK3—atherosclerosis	5.39e-06	2.18e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—AKT1—atherosclerosis	5.39e-06	2.18e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—TGFB1—atherosclerosis	5.23e-06	2.11e-05	CbGpPWpGaD
Afatinib—LCK—Disease—AKT1—atherosclerosis	5.19e-06	2.1e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—ALB—atherosclerosis	5.18e-06	2.09e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—NOS3—atherosclerosis	4.95e-06	2e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PTGS2—atherosclerosis	4.53e-06	1.83e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—AKT1—atherosclerosis	4.21e-06	1.7e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—IL6—atherosclerosis	4.09e-06	1.65e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—IL6—atherosclerosis	3.94e-06	1.59e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—AKT1—atherosclerosis	3.77e-06	1.53e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—AKT1—atherosclerosis	3.64e-06	1.47e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—AKT1—atherosclerosis	2.28e-06	9.21e-06	CbGpPWpGaD
